Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

References

• Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005;13:80–84.
   PubMed Web of Science ®Google Scholar
• Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010;6:1073–1084.
   PubMed Web of Science ®Google Scholar
• Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012;684:1–7.
   PubMed Web of Science ®Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–2482.
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–1577.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441–1449.
   PubMed Web of Science ®Google Scholar
• Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823–832.
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10: 115–124.
   PubMed Web of Science ®Google Scholar
• Aapro M, Fabi A, Nole F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21: 1083–1088.
   PubMed Web of Science ®Google Scholar
• Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 2012;20:1507–1514.
   PubMed Web of Science ®Google Scholar
• Brugnatelli S, Gattoni E, Grasso D, et al. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 2011;97:362–366.
   PubMed Web of Science ®Google Scholar
• Celio L, Denaro A, Agustoni F, et al. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 2012;10:65–71.
   PubMedGoogle Scholar
• Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011; 19:1217–1225.
   PubMed Web of Science ®Google Scholar
• Feinberg B, Gilmore J, Haislip S, et al. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support Care Cancer 2012;20:615–623.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer 2012;20:653–656.
   PubMed Web of Science ®Google Scholar
• Noor R, Bedikian AY, Mahoney S, et al. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 2012;20:2583–2588.
   PubMed Web of Science ®Google Scholar
• Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 2012;66:753–757.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Landi C, Caruso JP, et al. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin lymphoma patients. Leuk Res 2012;36:182–185.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Morrow G, Balu S, et al. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin 2011;27:1613–1622.
   PubMed Web of Science ®Google Scholar
• Di Renzo N, Montanini A, Mannina D, et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 2011;19:1505–1510.
   PubMed Web of Science ®Google Scholar
• Basch E, Hesketh PJ, Kris MG, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2011;7:395–398.
   PubMedGoogle Scholar
• Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl. 5):v232–v243.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical PracticeGuidelines in Oncology – Non-Hodgkin lymphomas. Available from: http://www.nccn.org
   Google Scholar
• Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003;11:522–527.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology – Antiemesis. Version 1.2012. Available from: http://www.nccn.org.
   Google Scholar
• Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012;20:1435–1439.
   PubMed Web of Science ®Google Scholar
• Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 2012;20:2343–2347.
   PubMed Web of Science ®Google Scholar